Stanford Researchers Discover “Natural Ozempic” Molecule BRP for Weight Loss
Weight loss treatment is on the verge of a significant shift. Scientists at Stanford Medicine have identified a naturally occurring molecule that mimics the appetite-suppressing effects of semaglutide—the active ingredient in Ozempic—but without the debilitating side effects that often accompany current GLP-1 medications.
- The Molecule: A tiny peptide called BRP, discovered using artificial intelligence.
- The Benefit: Reduces appetite and body weight in animal studies without causing nausea, constipation, or muscle loss.
- The Mechanism: Unlike Ozempic, BRP acts specifically in the hypothalamus of the brain.
- The Future: Clinical trials in humans are being planned.
How BRP Differs from Ozempic
While both BRP and semaglutide (Ozempic) target weight loss and appetite suppression, they operate through different biological pathways. Understanding this distinction explains why BRP may be better tolerated by patients.
Targeted Action vs. Widespread Effects
Semaglutide targets receptors found throughout the body, including the gut, pancreas, and brain. According to Assistant Professor of Pathology Katrin Svensson, PhD, this widespread presence is why Ozempic slows the movement of food through the digestive tract and lowers blood sugar, which can lead to gastrointestinal distress.
In contrast, BRP acts specifically in the hypothalamus, the region of the brain responsible for controlling metabolism, and appetite. By activating distinct groups of neurons, BRP offers a more precise approach to weight reduction, avoiding the systemic side effects associated with gut-level receptor activation.
The Role of AI in the Discovery
The discovery of BRP wasn’t a matter of chance; it required advanced technology. Researchers used artificial intelligence to analyze dozens of proteins known as prohormones.
Prohormones are biologically inert molecules. They only become active when cleaved by other proteins into smaller pieces called peptides. Some of these peptides then function as hormones to regulate energy metabolism. AI allowed the Stanford team to sift through these complex proteins to identify the specific peptide that could rival the effects of GLP-1 drugs.
Addressing GLP-1 Resistance
The discovery of BRP comes at a critical time, as new research highlights why current GLP-1 medications don’t work for everyone. A study published in Genome Medicine suggests that approximately 10% of the population may have “GLP-1 resistance” due to genetic variants.
In these individuals, GLP-1 hormone levels are higher than normal, but the hormone is less effective at regulating blood sugar. While it’s not yet clear if this resistance affects weight loss outcomes, the identification of alternative pathways—like the one BRP utilizes—could lead to more personalized, precision medicine for those who don’t respond to standard treatments.
What’s Next for BRP?
The research, published in Nature and led by senior research scientist Laetitia Coassolo, PhD, has already shown success in animal models. To move this discovery toward public availability, Dr. Katrin Svensson has co-founded a company dedicated to launching clinical trials in humans in the near future.
Comparison: BRP vs. Semaglutide (Ozempic)
| Feature | Semaglutide (Ozempic) | BRP Molecule |
|---|---|---|
| Primary Target | Brain, gut, and pancreas | Hypothalamus (Brain) |
| Common Side Effects | Nausea, constipation, muscle loss | None reported in animal tests |
| Method of Discovery | Pharmaceutical development | AI-driven prohormone analysis |
Frequently Asked Questions
Is BRP available for purchase now?
No. BRP is currently in the research and animal testing phase. Clinical trials for humans are being planned by the co-founded company of Dr. Katrin Svensson.
Does BRP cause muscle loss?
Based on early animal studies, BRP drives fat loss and improves metabolism without the significant muscle loss often seen with other weight-loss medications.
Why is it called “natural Ozempic”?
It is referred to as “natural” because it is a naturally occurring peptide identified by researchers, rather than a synthetic drug, though it mimics the appetite-suppressing results of Ozempic.